KP
Karen Prange
Director

Karen Prange insider trades: AtriCure (ATRC) stock buys and sales

Director, AtriCure Last trade Aug 5, 2026 54 Form 4 filings
$224K
Sold, last 12 months
2 sales
$0
Bought, last 12 months
0 buys
12
Open-market trades
since 2014
8
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Karen reports to the SEC

and 2 more companies

Open-market buys and sales

12 trades reported on SEC Form 4, newest first

DateStockTypeValue
Aug 5, 2026ATRC↓ Sell$138K
May 20, 2026ATRC↓ Sell$86K
Mar 5, 2025ATRC↓ Sell$233K
Jul 21, 2023VRAY↓ Sell$9K
Jun 8, 2023ATRC↓ Sell$34K
May 10, 2022VRAY↑ Buy$100K
Mar 8, 2016BSX↓ Sell$255K
Feb 8, 2016BSX↓ Sell$100K
Jul 7, 2015BSX↓ Sell$308K
Mar 3, 2015BSX↓ Sell$42K
Feb 27, 2015BSX↓ Sell$22K
Dec 10, 2014BSX↓ Sell$250K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other ATRC insiders

Open-market trades in the last 12 months

About Karen Prange's insider trades

Karen Prange is a director at AtriCure (ATRC). Since Dec 10, 2014, Karen has reported 1 open-market purchase worth $100K and 11 sales worth $1.5M on SEC Form 4. In the last 12 months: 2 sales ($224K).

Their filings also include grants and awards (30 filings), shares withheld for taxes (11 filings), option exercises (10 filings), shares returned to the company (2 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ATRC insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.